ReviewEmerging infectious diseases2021
Invasive Fusariosis in Nonneutropenic Patients, Spain, 2000-2015.
Review in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 againstJAC-antimicrobial resistance · 2026Article
- Invasive Fusariosis Among Patients with Acute Leukemia: A 12-Year Single-Center Experience in a Middle-Income Country.Mycopathologia · 2026Article
- Article
- Assessment of the molecular identification algorithm and its impact on antifungal susceptibilities against clinicalJAC-antimicrobial resistance · 2026Article
- Successful treatment of a resistant invasive disseminated Fusarium infection in an immunocompetent patient.Medical mycology case reports · 2025Article
- Clinical Features and Outcomes of InvasiveJournal of fungi (Basel, Switzerland) · 2025Article
- The Dual PathogenJournal of fungi (Basel, Switzerland) · 2025Review
- Multicenter Retrospective Study of Invasive Fusariosis in Intensive Care Units, France.Emerging infectious diseases · 2024Review
- Invasive fusariosis.Clinical microbiology reviews · 2023Review
- Pharmacodynamic and immunological interactions of amphotericin B formulations and voriconazole with human neutrophils against mature Scedosporium apiospermum and Fusarium spp. biofilms.The Journal of antimicrobial chemotherapy · 2023Article
- Non-Journal of fungi (Basel, Switzerland) · 2023Review
- Efficacy of Propolis Gel on Mature Biofilm Formed byJournal of fungi (Basel, Switzerland) · 2022Article
- Antifungal Susceptibility of 182 Fusarium Species Isolates from 20 European Centers: Comparison between EUCAST and Gradient Concentration Strip Methods.Antimicrobial agents and chemotherapy · 2021Article
- Pest categorisation ofEFSA journal. European Food Safety Authority · 2021Article
- Invasive Fusariosis in Patients with Hematologic Diseases.Journal of fungi (Basel, Switzerland) · 2021Review
- Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 12 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fusariosis (IF) is associated with severe neutropenia in patients with concurrent hematologic conditions. We conducted a retrospective observational study to characterize the epidemiology of IF in 18 Spanish hospitals during 2000-2015. In that time, the frequency of IF in nonneutropenic patients increased from 0.08 cases per 100,000 admissions in 2000-2009 to 0.22 cases per 100,000 admissions in 2010-2015. Nonneutropenic IF patients often had nonhematologic conditions, such as chronic cardiac or lung disease, rheumatoid arthritis, history of solid organ transplantation, or localized fusariosis. The 90-day death rate among nonneutropenic patients (28.6%) and patients with resolved neutropenia (38.1%) was similar. However, the death rate among patients with persistent neutropenia (91.3%) was significantly higher. We used a multivariate Cox regression analysis to characterize risk factors for death: persistent neutropenia was the only risk factor for death, regardless of antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.